We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of EQRx, Inc. (“EQRx” or the “Company”) (NASDAQ: EQRX),  in connection with its proposed acquisition by Revolution Medicines, Inc. (NASDAQ: RVMD) (“Revolution Medicines”).  Under the merger agreement, the Company’s shareholders will receive Revolution Medicines stock equal to $1.07 billion pursuant to a complex, blended formula providing for 20% thereof to be valued at $26 per share plus 80% thereof to be discounted 6% below the 5-day volume-weighted average Revolution Medicines share price around the time of the EQRx stockholder vote.

Weiss Law is investigating whether (i) EQRx’s board acted in the best interests of Company shareholders in agreeing to the merger,(ii) the merger consideration adequately compensates EQRx’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com